touchIMMUNOLOGY were delighted to speak with our expert faculty member Prof. Marcus Maurer (Charité – Universitätsmedizin Berlin, Germany) to learn more around our new society partner UCARE, the Urticaria Center of Reference and Excellence, to discuss raising awareness around urticaria, the current initiatives in place to increase physician and patient knowledge around urticaria and the challenges associated with diagnosis and management of urticaria and what UCARE is doing to overcome these.
- Could you tell us a little about UCARE and its objectives? (0:43)
- Which achievements are you most proud of in the last year? (1:38)
- What are your priorities for the year ahead? (2:37)
- What do you consider the most challenging aspects of the diagnosis and management of urticaria? (3:26)
- Could you tell us a little about your current and upcoming projects? (4:19)
Disclosures: Marcus Maurer is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Allerdia, Amgen, Aralez, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, FAES, Genentech, GIInnovation, Innate Pharma, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third HarmonicBio, UCB, and Uriach.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!